How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Zacks.com on MSN6d
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
BioSpace6h
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
BioSpace6d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Zacks.com on MSN6d
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
pharmaphorum6d
J&J's Spravato gets another lift with new FDA approval
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
Verywell Health on MSN4h
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Medical News Today1d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...